Krka, Accord And Xeris Pick Up European Nods
Rivals To Revlimid And Sutent Accompanied By GlucaGen Hybrid
The EMA’s CHMP has recommended granting pan-European marketing authorizations for Krka’s lenalidomide versions of Revlimid and Accord’s sunitinib rival to Sutent, as well as Xeris Pharmaceuticals’ glucagon hybrid rival to Glucagen.
